{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:11:07Z","timestamp":1787314267504,"version":"build-2736575974"},"reference-count":10,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report a case of severe hypertriglyceridemia (HTG) complicated by hyperviscosity syndrome as a possible adverse reaction to risankizumab-rzaa in a 49-year-old male with a history of longstanding uncontrolled type 2 diabetes, obesity, and coronary artery disease with prior ST-elevation myocardial infarction. On admission, the patient presented with xanthomatous plaques, chest and epigastric discomfort, and headache. Subsequent blood testing revealed severely elevated triglyceride (TG) levels at 7670\u2005mg\/dL (86.59\u2005mmol\/L) [reference range: &amp;lt;150\u2005mg\/dL; 1.69\u2005mmol\/L] and total cholesterol at 934\u2005mg\/dL (24.14\u2005mmol\/L) [reference range: &amp;lt;200\u2005mg\/dL; 5.17\u2005mmol\/L]. Triglyceride levels decreased and symptoms resolved with dietary restrictions and plasmapheresis. At follow-up, his TG remained elevated but improved, and he was advised to continue lipid-lowering medications as well as cessation of risankizumab. While the patient presented with high risk factors, we posit that the subacute presentation of severe HTG is a possible result of his recent course of risankizumab-rzaa therapy for management of psoriasis. This is noteworthy as pharmaceutical surveys and clinical trials do not list severe HTG as an adverse effect. Postmarketing surveillance studies are essential to confirm this potential association and monitor drug safety. In summary, this case highlights a possible link between risankizumab and severe HTG, emphasizing the importance of ongoing pharmacovigilance to identify and manage unexpected adverse effects associated with new medications.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae087","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T15:45:58Z","timestamp":1713973558000},"source":"Crossref","is-referenced-by-count":2,"title":["Severe Hypertriglyceridemia in a Patient With Metabolic Syndrome and Psoriasis on Risankizumab-Rzaa"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9029-5815","authenticated-orcid":false,"given":"Isra","family":"Abdulwadood","sequence":"first","affiliation":[{"name":"Alix School of Medicine, Mayo Clinic , Scottsdale, AZ 85259 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F","family":"De melo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C","family":"Scheel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-5160","authenticated-orcid":false,"given":"John P","family":"Bois","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"2024062702130137300_luae087-B1","doi-asserted-by":"crossref","first-page":"m3109","DOI":"10.1136\/bmj.m3109","article-title":"Management of hypertriglyceridemia","volume":"371","author":"Simha","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"2024062702130137300_luae087-B2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1567-5688(09)71810-0","article-title":"Severe hypertriglyceridemia: an indication for apheresis?","volume":"10","author":"Ewald","year":"2009","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"2024062702130137300_luae087-B3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2013current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2024062702130137300_luae087-B4","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/js.2019-00129","article-title":"Very severe hypertriglyceridemia in a large US county health care system: associated conditions and management","volume":"3","author":"Esparza","year":"2019","journal-title":"J Endocr Soc"},{"issue":"2","key":"2024062702130137300_luae087-B5","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1530\/EJE-13-0586","article-title":"Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism","volume":"170","author":"Verg\u00e8s","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2024062702130137300_luae087-B6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1517\/14656566.2013.798645","article-title":"Icosapent ethyl for the treatment of hypertriglyceridemia","volume":"14","author":"Ballantyne","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"2024062702130137300_luae087-B7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MOL.0000000000000679","article-title":"The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?","volume":"31","author":"Reeskamp","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"11","key":"2024062702130137300_luae087-B8","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1111\/trf.15532","article-title":"Efficacy of therapeutic plasma exchange in reducing the incidence of recurrent pancreatitis related to familial chylomicronemia","volume":"59","author":"Fitts","year":"2019","journal-title":"Transfusion"},{"issue":"6","key":"2024062702130137300_luae087-B9","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024062702130137300_luae087-B10","doi-asserted-by":"crossref","first-page":"1169735","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"2023","journal-title":"Front Immunol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/6\/luae087\/58340783\/luae087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/6\/luae087\/58340783\/luae087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T22:13:15Z","timestamp":1719439995000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae087\/7696982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,5,24]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae087","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,24]]},"article-number":"luae087"}}